PAVmed Toekomstige groei
Future criteriumcontroles 2/6
De verwachting is dat PAVmed de winst en omzet met respectievelijk 25.3% en 90% per jaar zal laten groeien, terwijl de winst per aandeel naar verwachting zal groeien met 136.1% per jaar.
Belangrijke informatie
25.3%
Groei van de winst
136.09%
Groei van de winst per aandeel
| Medical Equipment winstgroei | 16.2% |
| Inkomstengroei | 90.0% |
| Toekomstig rendement op eigen vermogen | n/a |
| Dekking van analisten | Low |
| Laatst bijgewerkt | 06 Jun 2026 |
Recente toekomstige groei-updates
Recent updates
Narratiefupdate • May 30
PAVM: Recalibrated Risk Assumptions Will Support Long Term Earnings Power
Analysts have lowered their PAVmed price target by $44, citing updated assumptions around discount rates, revenue growth, profit margins and future P/E that they believe better reflect the company’s current risk and return profile. Analyst Commentary Recent research on PAVmed has focused heavily on how updated assumptions around discount rates, revenue growth, profit margins and future P/E affect what analysts view as a fair value for the stock.Narratiefupdate • May 14
PAVM: Reset Expectations Around Execution Risk May Unlock Future Upside
Analysts have lowered their price target on PAVmed by $44 to reflect updated assumptions around discount rates, profit margins and forward P/E multiples highlighted in recent research. Analyst Commentary Recent research materials frame the lower price target as a reset around key inputs like discount rates, expected profit margins and the forward P/E multiple, rather than a simple call on near term share price moves.Narratiefupdate • Apr 26
PAVM: Revised Outlook And New Capital Raise Will Drive Future Upside
Analysts have reduced their price target on PAVmed by about $223, citing lower fair value estimates, a slightly higher discount rate, more moderate revenue growth assumptions, a modestly thinner profit margin outlook, and a lower future P/E, as reflected in recent Street research. Analyst Commentary Recent Street research points to a reduced price target on PAVmed, with analysts explaining the cut mainly through changes to their valuation framework rather than any single new data point.Narratiefupdate • Apr 07
PAVM: Updated Fair Value Work Will Support Future Upside Potential
Analysts cut their price target on PAVmed by $44, citing updated assumptions for fair value, discount rate, revenue growth, profit margin, and a higher future P/E to better align their outlook with recent research findings. Analyst Commentary Analysts updated their work on PAVmed by cutting the price target by $44 and resetting key inputs such as fair value estimates, discount rate, revenue growth assumptions, profit margin outlook, and the future P/E multiple.Narratiefupdate • Mar 24
PAVM: Reverse Split And New Capital Structure Will Support Future Upside
Analysts have kept their PAVmed fair value estimate steady at $510.00 per share, with a slightly higher discount rate and future P/E assumption guiding this unchanged price target. What's in the News PAVmed plans a special and extraordinary shareholders meeting on March 27, 2026, at 10:00 a.m. US Eastern Standard Time to vote on several governance and equity plan items, including potential director removal rules and equity plan share increases (Key Developments).Narratiefupdate • Mar 10
PAVM: Reverse Split Will Support Future Upside Potential
Analysts now set their price target for PAVmed at $510.00, compared with the prior $285.00, citing updated assumptions on the discount rate, revenue growth, profit margin, and future P/E. What's in the News PAVmed plans a special or extraordinary shareholders meeting on March 27, 2026, signaling upcoming decisions that require stockholder input (Key Developments).Narratiefupdate • Feb 23
PAVM: Reverse Split And Preferred Financing Will Support Future Upside Potential
Analysts have slightly lifted their price target on PAVmed to $285.00, reflecting updated assumptions around the discount rate, profit margin and future P/E that leave their overall valuation view broadly unchanged. What's in the News PAVmed closed a private placement on February 4, 2026, issuing $30,000,000 of Series D Convertible Preferred Stock, along with warrants that can be exercised for up to an additional $30,000,000 of Series D Convertible Preferred Stock.Narratiefupdate • Feb 08
PAVM: Reverse Split And Preferred Financing Will Support Future Share Upside
Analysts have kept their PAVmed price target steady at US$285.00, with the unchanged fair value supported by a slightly lower discount rate, a modestly higher profit margin assumption, and a small reduction in the very high future P/E multiple used in their models. What's in the News On February 4, 2026, PAVmed closed a private placement of US$30,000,000 in newly designated Series D Convertible Preferred Stock, with attached warrants that can be exercised for up to an additional US$30,000,000 of Series D Convertible Preferred Stock, callable if a positive draft Medicare local coverage determination is published for the EsoGuard Esophageal DNA Test offered by subsidiary Lucid Diagnostics, Inc.Narratiefupdate • Jan 25
PAVM: Reverse Split Will Aim To Support Future Share Upside
Analysts have reduced their price target on PAVmed to US$285.00. This reflects slightly adjusted assumptions regarding the discount rate, profit margin and future P/E, while leaving their overall view of fair value essentially unchanged.Narratiefupdate • Jan 09
PAVM: Reverse Split Will Support Future Upside Potential
Analysts have lifted their price target on PAVmed to US$285.00 from US$9.50, reflecting updated fair value work alongside modest tweaks to the discount rate, profit margin assumptions, and a slightly lower future P/E multiple. What's in the News PAVmed plans a 1 for 30 reverse stock split of its common stock, effective January 2, 2026 at 12:01 a.m. Eastern Time, with shares expected to begin trading on a split adjusted basis that same day on the Nasdaq Capital Market under the symbol PAVM (Key Developments).Narratiefupdate • Dec 25
PAVM: Reverse Split And Reduced Share Count Will Support Future Upside Potential
Analysts have modestly raised their price target on PAVmed to 9.50 dollars per share, reflecting expectations for slightly stronger long term revenue growth despite a higher perceived risk profile and a somewhat lower future earnings multiple. What's in the News Stockholders approved an amendment to PAVmed’s certificate of incorporation authorizing a reverse stock split in a ratio between 1 for 10 and 1 for 30, to be set by the board of directors in its discretion (Key Developments).Narratiefupdate • Dec 11
PAVM: Reverse Split And Tighter Share Structure Will Reduce Dilution Risk
Analysts have raised their price target on PAVmed significantly, from approximately 5.55 dollars to 9.50 dollars, citing expectations for faster revenue growth, meaningfully improved profit margins, and a lower perceived risk profile. What's in the News Stockholders approved an amendment to PAVmed's certificate of incorporation authorizing a reverse stock split in a range of 1-for-10 to 1-for-30, at the board's discretion (Special Meeting, Dec.Analyseartikel • Nov 18
Is PAVmed (NASDAQ:PAVM) Using Debt Sensibly?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...
Nieuw narratief • Jan 24
Veris Health's NIH Grant May Boost Future Revenue, But Financing Uncertainty Could Persist
Strategic restructuring and subsidiary deconsolidation aim to strengthen the financial structure and improve net margins.Analyseartikel • Jan 29
Are Investors Undervaluing PAVmed Inc. (NASDAQ:PAVM) By 28%?
Key Insights PAVmed's estimated fair value is US$3.18 based on 2 Stage Free Cash Flow to Equity PAVmed is estimated to...Analyseartikel • Aug 17
Is PAVmed (NASDAQ:PAVM) Using Debt In A Risky Way?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Seeking Alpha • Aug 16
PAVmed Non-GAAP EPS of -$0.17 beats by $0.03
PAVmed press release (NASDAQ:PAVM): Q2 Non-GAAP EPS of -$0.17 beats by $0.03. PAVmed had cash and cash equivalents of $65.2 million as of June 30, 2022, compared with $77.3 million as of December 31, 2021. Shares +3.03%.Seeking Alpha • Jul 05
PAVmed Continues To Have Lots Of Potential But EsoGuard Determines Short-Term Progress
PAVmed established an interesting hub and spoke business model with joint services and selling stakes in commercially ready technologies. This opens up new financing streams and potentially a lot of value creation for PAVmed shareholders. But near-term, the viability depends on things going right for Lucid, which is not guaranteed. Still, given the potential, we think PAVM is cheap enough for a speculative position. PAVmed (PAVM) shows how risky small-cap growth stocks can be, unfortunately. We saw, and still see, a lot of potential as they have a number of technologies and devices that are promising and some of these are already FDA approved. Then they did something smart, they started to treat PAVmed as a sort of holding company with centralized services, with the plan of creating public offerings for those divisions which were in commercial or near-commercial stage. This has a number of advantages: Shared resources and efficiencies in central functions Monetizing their most mature solutions whilst still keeping a majority stake Tapping the capital markets without diluting the shares of PAVmed The markets were also on board with this as the stock price went to $10 but the enthusiasm for small growth stocks has turned 180 degrees and execution delays did further damage. FinViz However, we think the company still has a lot going for it and at $1 there is room for recovery in the share price if the company executes according to plan. Lucid The first division that was put on the market was Lucid (LUCD), which has commercial-stage EsoCheck/Guard the only nonendoscopic biomarker screening test for treating gastroesophageal reflux disease who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. The EsoCheck/EsoGuard is a simple alternative for an invasive endoscopy. Or, from the LUCD Q1/22CC: "Lucid Diagnostics is a commercial-stage cancer prevention diagnostics company focused on the millions of chronic heartburn patients who are at risk of developing highly lethal esophageal cancer. Unlike other common cancers, mortality rates are high even in their earlier stages. So preventing deaths requires us to detect esophageal pre-cancer, which occurs in approximately 5% to 15% of that risk chronic heartburn patients." PAVmed has a 76% stake worth $65M. The ACG (American College of Gastroenterology) recently updated its clinical guideline including non-endoscopic biomarker screening. EsoCheck/Guard is the only one on the market. Prior hesitations about women needing tests disappeared, more than doubling the target population. Medicare contractor Palmetto GBA's MoIDX program published a foundational LDC (local Medicare coverage determination) for public review providing criteria for a category of testing. This happened before the American College guidelines so it didn't take its recommendation for non-endoscopic biomarker testing on board but the public review will likely take these ACG recommendations onboard. Lucid executed 533 EsoGuard tests in Q1 +500% Y/Y +76% Q/Q. Its sales force is expanding. The company is expanding its test centers, now in 7 western cities, 9 additional planned this year all at once (these test centers are mostly just a sales rep and a practitioner, and a small office). In some of these cities, they already have a presence. "Single nurse practitioner can reasonably perform 20 EsoCheck procedures on a normal workday. Each test center covers its personal and medical office lease costs with only a couple of reimbursed tests per week." (LUCD Q1/22CC). The pilot EsoGuard telemedicine program launched on Dec/21, advertising in Phoenix. Lucid DX Labs is now CLIA certified (Feb/22) so the company can transition from the commercial lab (requiring fixed monthly payments). The transition toward direct billing will cause a pause in out-of-network receipts. Reimbursement: our first commercial payer agreement with MediNcrease Health Plans (8M lives) EsoGuard $2.5K (Medicare $1.9K and out of network between $1K and $1.3K). There is also progress with Medicare reimbursement. Veris Health Launched in June 2021 with the acquisition of Oncodisc PAVmed has an 81% stake. Veris Health is a digital health company developing the first intelligent implantable vascular access port with biologic sensors and wireless communication to improve personalized cancer care through remote patient monitoring. "The Veris Technology is designed to allow oncologists to detect early signs of common cancer-related complications, provide longitudinal trends of physiologic and clinical data, offer data-driven risk management tools for precision oncology and incorporate additional prospects for substantial value creation through data monetization and biotherapeutic clinical trial support." (Q1/22CC) It runs on a SaaS service leveraging existing reimbursement codes for remote patient monitoring It has a partnership with Microsoft (MSFT). The first commercial launch will be later this year. Its core is provided by three interconnected software platforms, a patient smart app, a cloud-based software platform to which the app uploads and an app for the clinical team to engage with the cloud-based platform. Hiring four experts, who are also available for PAVmed platform. There are also three device projects, Mercury, Venus and Solis "Veris Solar combines the software platform with existing wearable and connected medical devices. This will allow us to launch the first commercial product and get valuable initial real-world experience with the software platform and engage with early adopters. We are on schedule to launch Veris Solar later this year." (Q1/22CC) Veris Mercury is their own implantable smart device. The launch is expected next year. Veris Venus "will offer the fully integrated intelligent vascular access port utilizing many of the same components Venus Mercury - as Veris Mercury, excuse me. We will seek to advance this product through the FDA's de novo pathway, but EU regulations for the integrated device will be less onerous and could allow a classic Europe first strategy" (Q1/22CC). CarpX Limited commercial release, waiting for product improvements Development of a next-generation CarpX device that incorporates integrated ultrasound imaging, facilitating the procedure. FDA submission 2023 NextFlo The small redesign hasn't yet delivered repeatability of data consistency so FDA submission is still some way off PortIO The first maintenance-free long-term vascular access device First clinical trial in Colombia ongoing EsoCure endoscopically treat esophageal precancer Animal studies show it compares favorably to Medtronic's Barrick device (market-leading) Business development The company has a R&D pipeline for new products in various stages of development Hired an experienced manager For possible M&A, management sees good opportunities in areas that are synergistic (particularly smart device technologies), valuations much reduced Finances There was $189K EsoGuard revenue from fixed contract ResearchDX (which terminated 25/2/22), but going forward they bill payers directly with their own lab. While March had a record number of test, they didn't bill during the month, waiting for Q2 for the new revenue cycle provider comes online. So suppose they did 200 tests in March and the few days of February at $1K-$1.3K each, they're running at $250K a month and that number is surely going to increase with more tests and greater reimbursement coverage.Seeking Alpha • Dec 24
Start Accumulating PAVmed
The shares of the company are extremely volatile as visibility into the financial future of the company is limited. However, we do think that, while certainly not devoid of risk, the shares potentially contain much more value, given Lucid's addressable market and the rapid build-up of its commercial infrastructure. Add to that the opportunities for some of its other products, and given the recent share sale and the companies should be able to proceed for quite a while. Commercial efforts ensued slower than hoped, and the company is experiencing headwinds from the pandemic, leading to considerable weakness in the share price.Analyseartikel • Sep 02
We Think PAVmed (NASDAQ:PAVM) Can Afford To Drive Business Growth
Just because a business does not make any money, does not mean that the stock will go down. Indeed, PAVmed...Seeking Alpha • Aug 23
PAVmed: Long Term Investment Case Remains Despite Weak Q2
EsoGuard/EsoCheck showed pretty slow growth in Q2 but momentum should improve as the company starts targeting consumers and PCPs directly and launches into Europe. Momentum for PAVM's pipeline products remains strong, and the company remains on track to get 3-4 products on the market by the end of 2022. In addition, subsidiary Veris Health is in talks with Microsoft which could lead to an eventual partnership. The valuation of the company remains low at $500mil despite the incredible momentum the company is showing and the clear disruptiveness of each of its products.Winst- en omzetgroeiprognoses
| Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
|---|---|---|---|---|---|
| 12/31/2027 | 1 | -18 | N/A | -20 | 2 |
| 12/31/2026 | 0 | -21 | N/A | -14 | 2 |
| 3/31/2026 | 0 | -28 | -6 | -6 | N/A |
| 12/31/2025 | 0 | -4 | -5 | -5 | N/A |
| 9/30/2025 | 0 | -1 | -4 | -4 | N/A |
| 6/30/2025 | 1 | 70 | -11 | -12 | N/A |
| 3/31/2025 | 2 | 72 | -22 | -22 | N/A |
| 12/31/2024 | 3 | 32 | -33 | -34 | N/A |
| 9/30/2024 | 4 | 15 | -46 | -46 | N/A |
| 6/30/2024 | 4 | -67 | -48 | -48 | N/A |
| 3/31/2024 | 3 | -71 | -49 | -49 | N/A |
| 12/31/2023 | 2 | -66 | -52 | -52 | N/A |
| 9/30/2023 | 2 | -71 | -56 | -57 | N/A |
| 6/30/2023 | 1 | -79 | -69 | -65 | N/A |
| 3/31/2023 | 1 | -90 | -79 | -75 | N/A |
| 12/31/2022 | 0 | -89 | -76 | -71 | N/A |
| 9/30/2022 | 1 | -86 | -79 | -71 | N/A |
| 6/30/2022 | 1 | -72 | -64 | -60 | N/A |
| 3/31/2022 | 1 | -58 | -48 | -44 | N/A |
| 12/31/2021 | 1 | -51 | -44 | -41 | N/A |
| 9/30/2021 | 0 | -42 | -31 | -31 | N/A |
| 6/30/2021 | N/A | -35 | -29 | -28 | N/A |
| 3/31/2021 | N/A | -30 | -27 | -27 | N/A |
| 12/31/2020 | N/A | -35 | -22 | -22 | N/A |
| 9/30/2020 | N/A | -32 | -19 | -19 | N/A |
| 6/30/2020 | N/A | -30 | -16 | -16 | N/A |
| 3/31/2020 | N/A | -28 | -13 | -13 | N/A |
| 12/31/2019 | N/A | -17 | N/A | -13 | N/A |
| 9/30/2019 | N/A | -17 | N/A | -12 | N/A |
| 6/30/2019 | N/A | -17 | N/A | -11 | N/A |
| 3/31/2019 | N/A | -19 | N/A | -10 | N/A |
| 12/31/2018 | N/A | -19 | N/A | -9 | N/A |
| 9/30/2018 | N/A | -12 | N/A | -7 | N/A |
| 6/30/2018 | N/A | -14 | N/A | -8 | N/A |
| 3/31/2018 | N/A | -10 | N/A | -7 | N/A |
| 12/31/2017 | N/A | -10 | N/A | -7 | N/A |
| 9/30/2017 | N/A | -12 | N/A | -6 | N/A |
| 6/30/2017 | N/A | -9 | N/A | -5 | N/A |
| 3/31/2017 | N/A | -9 | N/A | -6 | N/A |
| 12/31/2016 | N/A | -6 | N/A | -4 | N/A |
| 9/30/2016 | N/A | -5 | N/A | -4 | N/A |
| 6/30/2016 | N/A | -3 | N/A | -3 | N/A |
| 3/31/2016 | N/A | -2 | N/A | -2 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: De verwachting is dat PAVM de komende 3 jaar verliesgevend zal blijven.
Winst versus markt: De verwachting is dat PAVM de komende 3 jaar verliesgevend zal blijven.
Hoge groeiwinsten: De verwachting is dat PAVM de komende 3 jaar verliesgevend zal blijven.
Omzet versus markt: De omzet van PAVM ( 90% per jaar) zal naar verwachting sneller groeien dan de markt US ( 12.5% per jaar).
Hoge groei-inkomsten: De omzet van PAVM ( 90% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van PAVM naar verwachting over 3 jaar hoog zal zijn
Ontdek groeibedrijven
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/06/11 23:04 |
| Aandelenkoers aan het einde van de dag | 2026/06/11 00:00 |
| Inkomsten | 2026/03/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
PAVmed Inc. wordt gevolgd door 3 analisten. 2 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Edward Woo | Ascendiant Capital Markets LLC |
| Raymond Myers | Benchmark Company |
| Anthony Vendetti | Maxim Group |